Form D · Biotechnology
Moderna Therapeutics, Inc.
Cambridge, MA · CIK 0001682852
Offering snapshot reported Aug 24, 2016 · SEC filing
- Reported sold
- $451M Offering amount: $600M
- Investors reported
- 72 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2016 | Initial | $451,369,079 | No comparison | 72 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-269500
Source: Form D, filed Aug 24, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Noubar Afeyan | Director |
| Lee Babiss | Director |
| Stephane Bancel | Director, Executive |
| Stephen Hoge | Executive |
| Peter Hutt | Director |
| James R. Kasinger | Executive |
| Lorence Kim | Executive |
| Robert Langer | Director |
| John Mendlein | Director |
| Elizabeth Nabel | Director |
| Henri Termeer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Technology Square
Cambridge, MA, 02139
Cambridge, MA, 02139